Sistema de Información Esencial en Terapéutica y Salud

@SIETES7

Última actualización: 19/7/2019
SIETES contiene 92793 citas

 
 
 1 a 6 de 6 
Presentar resultados
Seleccionar todas
1. Cita con resumen
Johnson ES, Bartman BA, Briesacher BA, Fleming NS, Gerhard T, Kornegay CJ, Nourjah P, Sauer B, Schumock GT, Sedrakyan A, Sürmer T, West SL, Schneeweiss S. The incidence user design in comparative effectiveness research. Pharmacoepidemiol Drug Saf 2013;22:1-6. [Ref.ID 94655]
2. Cita con resumen
Winterstein AG, Gerhard T, Kubilis P, Saidi A, Linden S, Crystal S, Zito J, Shuster JJ, Olfson M. Cardiovascular safety of central nervous system stimulants in children and adolescents: population based cohort study. BMJ 2012;345:16. [Ref.ID 93565]
3. Cita con resumen
Winterstein AG, Gerhard T, Kubilis P, Saidi A, Linden S, Crystal S, Zito J, Shuster JJ, Olfson M. Cardiovascular safety of central nervous system stimulants in children and adolescents: population based cohort study. BMJ 2012;345:1-12. [Ref.ID 92709]
4.Tiene citas relacionadas Cita con resumen
Huybrechts KF, Gerhard T, Crystal S, Olfson M, Avorn J, Levin R, Lucas JA, Schneeweiss S. Differential risk of death in older residents in nursing homes prescribed specific antipsychotic drugs: population based cohort study. BMJ 2012;344:16. [Ref.ID 92610]
5. Cita con resumen
Winterstein AG, Gerhard T, Shuster J, Zito J, Johnson M, Liu H, Saidi A. Utilization of pharmacologic treatment in youths with attention deficit/hyperactivity disorder in Medicaid Database. Ann Pharmacother 2008;42:24-31. [Ref.ID 82000]
6. Cita con resumen
Winterstein AG, Gerhard T, Shuster J, Johnson M, Zito JM, Saidi A. Cardiac safety of central nervous system stimulants in children and adolescents with attention-deficit/hyperactivity disorder. Pediatrics 2007;120:1494-501. [Ref.ID 81805]
Seleccionar todas
 
 1 a 6 de 6